Key Highlights
- AnteoTech (ASX:ADO) delivered 40 litres each of two battery additives to customers for scale-up and Manufacturing trials.
- The company signed battery separator and prototype Supply agreements during the September quarter.
- A July diagnostic material shipment accounted for AUD 134,138 of quarterly customer receipts.
- Cash and cash equivalents ended the quarter at AUD 11 million after an AUD 1.91 million research tax incentive receipt.
AnteoTech (ASX:ADO), a supplier of chemicals and materials for lithium-ion batteries and diagnostic tests, reported customer trials and development agreements in its update for the three months ended 30 September 2026. Its 29 October filing described work on battery separators, prototype cells and immunoassay materials. The unaudited Cash Flow report also showed how a research tax incentive contributed to quarterly operating cash flow.
Battery additive trials
Prospective customers in Asia and the United States continued evaluating the company’s performance additives. Two customers received 40 litres each of Anteo S and Anteo C for scale-up and manufacturing trials. AnteoTech said the Anteo S delivery followed smaller evaluations and was its largest single-volume sample shipment for that product to date. A US customer separately requested indicative Volume pricing and planned to trial 30 litres of SiMRAX in several hundred demonstration cells.
The company signed a binding collaboration and sales agreement with Xerabrid to combine Anteo S with Xerabrid’s ceramic-coated battery separator. Seven prospective customers requested samples. Requests included up to 1,000 metres of separator material made using roll-to-roll manufacturing. The September report expected delivery before the end of calendar 2026.
Prototype cell work
Ultranode 95 cylindrical cells were assembled, formed and tested at a US battery innovation facility. AnteoTech was continuing to refine the 18650-format cells before supplying prototypes for prospective customer evaluation. It also signed a battery design and prototyping supply agreement with Airspeeder covering work for an electric vertical take-off and landing application.
At a separate customer program, Ultranode 70 met a cycle-life measure agreed with Wyon. Cells made in Wyon’s commercial format retained 70% of capacity after 500 cycles. The Quarterly Report said Wyon was identifying and engaging prospective end customers. AnteoTech also reported continuing negotiations on two non-exclusive development agreements for Ultranode 95 in the United States.
Life sciences products and receipts
AnteoTech delivered its July AnteoBind shipment to the Serum Institute of India under a five-year take-or-pay agreement and recognised the shipment as FY27 revenue. The customer continued evaluating prototype AnteoBind activated plates. Separately, AnteoTech completed the initial stage of a collaborative chemiluminescent immunoassay development program with a global life sciences company. Work had started on the next stage.
The company introduced AnteoBind NXT kits for chemiluminescent immunoassays and prototype activated plates at a US industry event. It commissioned independent testing in the US and the UK for lateral flow, multiplex and chemiluminescent immunoassay applications. The filing described follow-up meetings and sample requests, alongside a trial expansion of the US Business development network.
September cash flow and upcoming work
Customer receipts totalled AUD 200,134, including the July shipment. AnteoTech received AUD 1,905,639 under the Research and Development tax incentive linked to eligible FY26 expenditure across its two businesses. Net operating cash outflow was AUD 27,932. Half of the AUD 11 million quarter-end balance was held on a six-month term deposit due to mature in December. Looking ahead from the October filing, management said its focus was on supporting customer tests, converting evaluations into sales and pursuing partnerships in both operating divisions. The planned Leadership transition continued alongside that work. AnteoTech announced after quarter-end that Luke Oxenham would start as chief financial officer and company secretary on 23 November. Outgoing chief financial officer Scott Waddell’s resignation was effective 4 December. The October filing said the transition was already underway.






Please wait processing your request...